Pharma Firms

Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business

The company has registered 10% growth in revenues at Rs 4,431.8 cr for the quarter under review from Rs 4,016.6 cr in the year-ago period

Pharma export growth in FY20 down to single digit due to Covid: Pharmexcil

Export growth started declining in February and turned negative in March, at -23.24 per cent

GSK to offload HUL stake worth Rs 26,000 cr in largest secondary sale

Over 133 million shares, or 5.7% of the paid-up capital, are being offered for Rs 1,850-1,950 to investors through a special block window

Ensure pharma units work smoothly amid Covid-19 lockdown: Govt to districts

8 Malaysians caught trying to leave India

Over 8,660 pharma firms claimed tax deduction during 2019-20: I-T dept

The matter will come up again in court on Monday

TCS bags $1.5-bn contract from US drug firm Walgreens Boots Alliance

The expansion of WBA and TCS strategic partnership is based on WBA's review of its IT operating model and vendor landscape

Cipla plans to partner Ayushman Bharat; start dialogue with insurance firms

There is a plan to identify a list of essential medicines, including antibiotics, painkillers, etc, which the company may supply to the Ayushman Bharat-empanelled hospitals.

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in US market

Ogivri will be launched at a competitive discount for customers to help ensure access and increase treatment options for patients

From Dr Reddy's to Cipla, pharma companies aren't out of the woods: Experts

The Street is cautious given multiple challenges in core markets of US and India

From auto to banking, grumble of slowdown is getting louder for India Inc

The companies' combined net profit declined by 10.1 per cent yoy during June '19 quarter against 26.2 per cent yoy growth a year ago

Cipla urges govt to increase funds, ease policies for domestic pharma firms

In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health

Growth in US business likely to boost Q1 revenues of pharma companies

According to Edelweiss Securities, pharma sales to grow by 17 per cent YoY as US sales are expected to grow by 21 per cent YoY

Pharma funds remain in poor health amid headwinds on compliance

The BSE Healthcare Index has fallen 10 per cent in the last one year

Pharma companies are focusing on profitable brands, say analysts

Top 10 brands (of a company) account for more than 20 per cent of their domestic revenue in the case of most, analysts said

Regulatory issues bridle pharma returns, USFDA scrutiny a major hurdle

Impact of an escalation of the observations will hit their profit estimates over the next couple of years

US antitrust probe singes India's pharmaceutical firms; Sun Pharma falls 9%

44 states have alleged the drugmakers of price fixing

Returns down from US generic drugs market for Indian pharma firms

This decline was primarily for two reasons. One, commoditisation of generics led to price erosion. Two, investments increased in both R&D and in expansion

Drugs for rare diseases, ones innovated in India to go out of price control

Around 17 per cent of the Rs 1.2-trillion domestic pharma market is currently under price control

Lupin to Cipla, pharma firms on course to shed 'underperformer' tag in FY19

Easing of pricing pressures, launch of limited competition drugs in the US, weak rupee are key triggers

Soon, uniform inspection norms for pharma units; govt to form advisory body

The government is also mooting a cooperative manufacturing model for small units